Targeted pill tested against aggressive brain cancer
NCT ID NCT06105619
Summary
This study is testing whether an oral capsule called vebreltinib (PLB1001) can help people with a specific type of recurrent brain cancer live longer than standard chemotherapy. It is for adults with glioblastoma that has returned after initial treatment and who have a particular genetic change called the ZM fusion gene. Participants are randomly assigned to receive either the vebreltinib capsules or one of two standard chemotherapy regimens.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100070, China
Conditions
Explore the condition pages connected to this study.